Toxicity of Bupropion Overdose Compared With Selective Serotonin Reuptake Inhibitors.

OBJECTIVES

Adolescent depression and attempted and completed suicide are increasing in the United States. Because suicide is often impulsive, the means of self-harm are frequently items of convenience like medication. Authors of a recent study compared tricyclic antidepressant overdose to bupropion overdose. Fluoxetine and escitalopram are the only agents with Food and Drug Administration approval for pediatric depression, but off-label bupropion prescriptions are common. We sought to compare the effects of selective serotonin reuptake inhibitors (SSRIs) and bupropion in overdose.

METHODS

This was an analysis of the National Poison Data System from June 2013 through December 2017 for adolescent (ages 10-19) exposures to SSRIs or bupropion coded as "suspected suicide." Demographics, clinical effects, therapies, and medical outcome were analyzed.

RESULTS

There were 30 026 cases during the study period. Sertraline and fluoxetine accounted for nearly 60%, whereas bupropion was reported in 11.7%. Bupropion exposure was significantly associated with death (0.23% vs 0%; < .001) or serious outcome (58.1% vs 19%; < .001) as well as the 10 most common clinical effects, including seizures (27.0% vs 8.5%; < .001) and hallucinations (28.6% vs 4.3%; < .001). Bupropion exposure was significantly associated with the need for cardiopulmonary resuscitation (0.51% vs 0.01%; < .001), intubation (4.9% vs 0.3%; < .001), vasopressors (1.1% vs 0.2%; < .001), and benzodiazepines (34.2% vs 5.5%; < .001). There was a significant increase in all exposures and in proportion of serious outcomes over time.

CONCLUSIONS

Adolescents who attempt self-harm are at higher risk for serious morbidity and poor outcomes with bupropion than with SSRIs. These risks, and the patient's propensity for self-harm, should be evaluated when therapy with bupropion is considered.